BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX)

Q4 2019 13F Holders as of 31 Dec 2019

Type / Class: Equity / Common Stock, $0.01 par value per share
Shares outstanding: 209,618,986
Number of holders: 131
Total 13F shares, excl. options: 137,257,236
Shares change: +34,903,234
Total reported value, excl. options: $473,298,973
Value change: +$126,158,746
Put/Call ratio: 31.19%
Number of buys: 86
Number of sells: -42
Price: $3.45

Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q4 2019

160 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q4 2019.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 137,257,236 shares of 209,618,986 outstanding shares and own 65.48% of the company stock.
Largest 10 shareholders include BlackRock Inc. (12,150,211 shares), BAKER BROS. ADVISORS LP (10,946,166 shares), MILLENNIUM MANAGEMENT LLC (9,940,677 shares), JANUS HENDERSON GROUP PLC (9,408,481 shares), Point72 Asset Management, L.P. (8,382,900 shares), VANGUARD GROUP INC (8,121,631 shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (6,375,143 shares), CITADEL ADVISORS LLC (5,955,979 shares), STATE STREET CORP (5,492,943 shares), and UBS Group AG (5,488,287 shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

Investor	Option	Weight %	Change %	Value $	* Price $	Shares	Share Change	Activity	Report Period

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.